pepgen inc shares were up 19 to 617 after the company said it saw positive results from its completed trial of pgnedo51 its lead product candidate for the treatment of certain duchenne muscular dystrophy patients the biotechnology companys phase 1 hnv trial of pgnedo51 was a single ascending dose clinical trial evaluating the safety and tolerability of pgnedo51 in 32 healthy adult males oligonucleotide tissue concentration and exon skipping also were assessed the trial met its primary endpoint assessing the safety profile of pgnedo51 at pharmacologically relevant doses pgnedo51 was generally well tolerated pepgen now plans to begin a phase 2a multiple ascending dose clinical trial in dmd patients in the first half of 2023 all participants completed the trial there were no discontinuations the majority of treatmentemergent adverse events were assessed as mild and resolved without any intervention at 10 mgkg there were only grade 1 adverse events the stock hit its 52week low of 432 last friday and is down 48 in the last three months